FDA Brief

Warning letters Food

FDA warning letter to

Great Lakes Gelatin Company

LowIssued May 10, 2021Posted May 25, 2021Office of Human and Animal Food Operations East-VI

FDA warned Great Lakes Gelatin that its collagen products were promoted as unapproved drugs for disease treatment.

What happened

FDA reviewed the company’s website in March–May 2021, along with its Facebook, Pinterest, and YouTube pages, and found product claims and testimonials that Collagen Hydrolysate, Keto Collagen + MCT, and Collagen Endurance Plus treat or prevent disease. FDA said the claims include reduced joint pain, osteoporosis and osteoarthritis treatment or prevention, gastrointestinal healing, and ulcer prevention. The letter also cited scientific publications used on the website as evidence of intended drug use.

What FDA found

  1. FDA said the website claims and testimonials made the collagen products drugs because they were intended to cure, mitigate, treat, or prevent disease.

    FD&C Act section 201(g)(1)(B) [21 U.S.C. 321(g)(1)(B)]
  2. FDA said the products are new drugs because they are not generally recognized as safe and effective for the claimed uses and have no FDA approval.

    FD&C Act sections 201(p), 301(d), and 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]
  3. FDA said the products are misbranded because they lack adequate directions for use for diseases that laypeople cannot safely diagnose or treat without a licensed practitioner.

    FD&C Act section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  4. FDA said scientific publication citations on the website can be evidence of intended disease treatment or prevention when used commercially in labeling.

    21 CFR 101.93(g)(2)(iv)(C)

What FDA wants

FDA asks the company to notify it in writing within 15 working days of receipt of the letter of specific steps taken to address the violations and prevent recurrence, with related documentation. If the company believes there is no violation, it must include its reasoning and supporting information.

Who should pay attention

  • dietary supplement brands selling collagen products
  • companies that use customer testimonials or scientific citations in product marketing
  • regulatory and marketing teams reviewing website and social media claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk